Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes Of One-Year Adjuvant Trastuzumab In Her2-Positive Early Breast Cancer From The Cyprus Nhs Payer Perspective

Introduction: This study is one of the first real-world cost-effectiveness analyses of one-year adjuvant trastuzumab used in HER2-positive early female breast cancer in comparison to chemotherapy alone. It is just the second one in Europe, the first one in Cyprus, and the fourth one worldwide ever carried out using real-world data. Methods: Using a Markov model (four health states), a cost-effectiveness analysis was carried out both over 20 years and for a lifetime horizon. The sampling method used in this study was the randomized sampling of 900 women. Results: The findings for the 20-year horizon showed that all trastuzumab arms were more cost-effective, with a willingness-to-pay threshold of only euro60,000 per quality-adjusted life year (QALY) [incremental cost-effectiveness ratios (ICER): euro40,436.10/QALY]. For the lifetime horizon, with thresholds of euro20,000, euro40,000, and euro60,000/QALY, all trastuzumab arms were found to be more cost-effective (ICER: euro17,753.85/QALY). Moreover, for the 20-year and the lifetime horizons, with thresholds of euro20,000/QALY, euro40,000/QALY, and euro60,000/QALY, the most cost-effective of the three subgroups (anthracyclines and then trastuzumab, no anthracyclines and then trastuzumab, and anthracyclines, taxanes, and trastuzumab) was that of anthracyclines and then trastuzumab (ICER: euro18,301.55/QALY and euro8954.97/QALY, respectively). Conclusions: The study revealed that adjuvant trastuzumab for one year in female HER2-positive early breast cancer can be considered cost-effective.